EpCAM and CSPG4 scFv based fusion proteins for the treatment of triple negative breast cancer
Year: 2018
Type: dissertation
Abstract: Triple-negative breast cancer (TNBC) defines a heterogeneous group of breast tumors lacking the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). It has the poorest prognosis of all breast cancer subtypes and high prevalence among young premenopausal women. Unlike other breast cancer subtypes, no effective targeted immunotherapy is currently available. Due to the heterogeneity of TNBC, no single receptor can be expected to be effective in targeting all TNBCs. Therefore, in this study, we set out to develop a panel of receptors for targeted therapies which can, together, include the majority of TNBC tumors. Through a literature search two markers stood out as suitable targets, EpCAM- overexpressed in 60% of TNBC and CSPG4- overexpressed in 20-40% of TNBC. EpCAM and CSPG4 are differentially expressed and their expression on TNBC tumor does not overlap. Therefore, novel single-chain variable fragment (scFv)-based human cytolytic fusion proteins (hCFPs) were constructed to target these receptors. Their activity and mechanism of action were compared to corresponding recombinant immunotoxins (ITs) utilizing the Pseudomonas Exotoxin A- deletion mutant (ETA’) as the toxic moiety. To target EpCAM expressing TNBC, a hCFP designated Gb-R201K-αEpCAM(scFv) was generated, in which an EpCAM-selective scFv was genetically fused to a human Granzyme B (Gb) mutant with reduced sensitivity to its natural inhibitor serpin B9. To target CSPG4 a CFP designated αCSPG4(scFv)-MAP was used, consisting of a CSPG4-selective scFv genetically fused to a functionally enhanced form of the human microtubule-associated protein (MAP) tau. In vitro studies confirmed specific binding, internalization and subsequent potent cytotoxic activity of both hCFPs, with IC50 values of 200-300 nM for Gb-R201K-αEpCAM(scFv) towards TNBC cell lines MDA-MB-453 and MDA-MB-468 and 200-400nM for αCSPG4(scFv)-MAP toward MDA-MB-231 and Hs 578T. In vivo studies in subcutaneous tumor models revealed that treatment of mice bearing MDA-MB-468 tumors with Gb-R201K-αEpCAM(scFv) inhibited tumor growth of up to 50 %. Treatment of mice bearing MDA-MB-231 tumors with αCSPG4(scFv)-MAP resulted in prominent inhibition of tumor growth and to tumor regression of more than 50%.Taken together, αCSPG4(scFv)-MAP and Gb-R201K-αEpCAM(scFv) appear to be clinically relevant and promising novel targeted agent for the treatment of TNBC.
Source: RWTH Publications (RWTH Aachen)
Institution: RWTH Aachen University
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W2791462642
